We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.
- Authors
Koutras, A K; Antonacopoulou, A G; Eleftheraki, A G; Dimitrakopoulos, F-I; Koumarianou, A; Varthalitis, I; Fostira, F; Sgouros, J; Briasoulis, E; Bournakis, E; Bafaloukos, D; Bompolaki, I; Galani, E; Kalogeras, K T; Pectasides, D; Fountzilas, G; Kalofonos, H P
- Abstract
The aim of the study was to evaluate the association of vascular endothelial growth factor (VEGF) genotypes with treatment efficacy in a randomized trial. This study compared two chemotherapy regimens (FOLFIRI versus XELIRI) combined with bevacizumab, as first-line treatment for metastatic colorectal cancer. DNA was extracted from blood samples of 173 patients participating in the trial. Genotyping was performed for selected SNPs (VEGF-1154, +936, -634, -2578 and -1498). All candidate genotypes were evaluated for associations with overall survival (OS), progression-free survival (PFS) and response rate (RR). There were no significant differences with respect to the distribution of genotypes in the treatment groups. The VEGF-1154 GG genotype was more frequent in patients not responding to treatment compared with responders (65.5 versus 39.8%, P = 0.032). Furthermore, the VEGF-1154 GG genotype was associated with inferior median OS compared with GA (hazards ratio = 1.68; 95% confidence interval: 1.10-2.57; P = 0.016) or with the alternative genotypes (GA and AA) combined (hazards ratio = 1.62; 95% confidence interval: 1.09-2.40; P = 0.017). In multivariate analysis, the VEGF-1154 GG genotype remained a significant adverse factor for OS. Our results support the potential predictive ability of VEGF genotypes in patients with metastatic colorectal cancer receiving irinotecan-based chemotherapy plus bevacizumab, in terms of RR and OS. However, current results should be validated prospectively, in larger cohorts.
- Publication
The pharmacogenomics journal, 2012, Vol 12, Issue 6, p468
- ISSN
1473-1150
- Publication type
Journal Article
- DOI
10.1038/tpj.2011.37